Alessandra Bennati

The neoadjuvant chemoimmunotherapy pathway has become the standard of care for patients with resectable, locally advanced non-small cell lung cancer without actionable mutations. Its increasing use has introduced novel technical challenges, as fibrotic changes, inflammatory...